Related Experiment Video

Updated: Jul 5, 2026

Bioenergetic Profile Experiment using C2C12 Myoblast Cells
07:20

Bioenergetic Profile Experiment using C2C12 Myoblast Cells

Published on: December 6, 2010

Review of clinic trials: agents targeting c-Met

Oyewale Abidoye1, Nadh Murukurthy, Ravi Salgia

  • 1Section of Hemato-logy/Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA.

Reviews on Recent Clinical Trials
|May 14, 2008
PubMed

Insights

This review covers the c-Met receptor tyrosine kinase, a key target in cancer therapy due to its role in cell proliferation and metastasis. Understanding c-Met biology and mutations informs new therapeutic strategies for cancer eradication.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Receptor tyrosine kinases (RTKs) regulate cell proliferation, motility, and metastasis.
  • The c-Met receptor tyrosine kinase (RTK) plays a significant role in cancer cell biology and is a crucial therapeutic target.
  • c-Met can be overexpressed, activated, amplified, or mutated in various cancers, often in response to its ligand, hepatocyte growth factor (HGF).

Purpose of the Study:

  • To review the biological and biochemical aspects of c-Met.
  • To detail various therapeutic strategies targeting c-Met.
  • To explore the potential for eradicating cancers where c-Met is a significant factor.

Main Methods:

  • Literature review of c-Met biology and therapeutic strategies.
  • Analysis of c-Met mutations in tyrosine kinase, juxtamembrane, and semaphorin domains.
  • Examination of pre-clinical and clinical data for c-Met targeted therapies.

Main Results:

  • c-Met mutations have been identified in multiple domains, including the tyrosine kinase, juxtamembrane, and semaphorin domains.
  • Targeting c-Met has shown promise pre-clinically.
  • Several clinical trials are ongoing for advanced cancers targeting c-Met.

Conclusions:

  • A comprehensive understanding of c-Met biology and its role in cancer is essential for developing effective therapeutic strategies.
  • Targeting c-Met offers a promising avenue for treating cancers driven by this receptor.
  • Further research into c-Met's diverse roles may lead to unique approaches for cancer eradication.

More Related Videos

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin (sh)RNA12:19

Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin (sh)RNA

Published on: February 12, 2020

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...